Hims Hers Health Inc (HIMS)vsTeva Pharma Industries Ltd ADR (TEVA)
HIMS
Hims Hers Health Inc
$22.02
-8.86%
HEALTHCARE · Cap: $5.67B
TEVA
Teva Pharma Industries Ltd ADR
$28.73
-2.41%
HEALTHCARE · Cap: $34.31B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 635% more annual revenue ($17.26B vs $2.35B). TEVA leads profitability with a 8.2% profit margin vs 5.5%. TEVA appears more attractively valued with a PEG of 1.47. TEVA earns a higher WallStSmart Score of 73/100 (B).
HIMS
Hold50
out of 100
Grade: D+
TEVA
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-538.6%
Fair Value
$3.47
Current Price
$22.02
$18.55 premium
Margin of Safety
+39.4%
Fair Value
$56.63
Current Price
$28.73
$27.90 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 25 in profit
Revenue surging 28.4% year-over-year
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.3%
Earnings expanding 40.0% YoY
Generating 1.0B in free cash flow
Areas to Watch
Trading at 9.3x book value
Distress zone — elevated risk
5.5% margin — thin
Operating margin of 2.7%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : HIMS
The strongest argument for HIMS centers on Return on Equity, Revenue Growth. Revenue growth of 28.4% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bear Case : HIMS
The primary concerns for HIMS are Price/Book, Altman Z-Score, Profit Margin. A P/E of 48.8x leaves little room for execution misses. Debt-to-equity of 2.34 is elevated, increasing financial risk.
Bear Case : TEVA
The primary concerns for TEVA are Altman Z-Score.
Key Dynamics to Monitor
HIMS profiles as a growth stock while TEVA is a value play — different risk/reward profiles.
HIMS carries more volatility with a beta of 2.61 — expect wider price swings.
HIMS is growing revenue faster at 28.4% — sustainability is the question.
TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (73/100 vs 50/100) and 11.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hims Hers Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?